Ralf H Wittenberg Selected Research

lumiracoxib (prexige)

1/2006

First-dose analgesic effect of the cyclo-oxygenase-2 selective inhibitor lumiracoxib in osteoarthritis of the knee: a randomized, double-blind, placebo-controlled comparison with celecoxib [NCT00267215].

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Ralf H Wittenberg Research Topics

Disease

3	Pain (Aches) 03/2015 - 01/2006
3	Osteoarthritis 02/2013 - 08/2004
1	Infections 03/2015
1	Sclerosis 02/2013
1	Atrophy 02/2013
1	Joint Dislocations 02/2013
1	Hypertrophy 02/2013
1	Developmental Dysplasia of the Hip 02/2013
1	Low Back Pain (Lumbago) 01/2012
1	Knee Osteoarthritis 01/2006
1	Synovitis 08/2004
1	Inflammation (Inflammations) 08/2004
1	Congenital Abnormalities (Deformity) 02/2002

Drug/Important Bio-Agent (IBA)

1	TitaniumIBA 03/2015
1	Analgesics (Analgesic Drugs)IBA 01/2006
1	lumiracoxib (prexige)IBA 01/2006
1	Celecoxib (Celebrex)FDA Link 01/2006
1	Dinoprostone (PGE2)FDA Link 08/2004
1	IsoenzymesIBA 08/2004
1	Prostaglandin-Endoperoxide Synthases (Cyclooxygenase)IBA 08/2004
1	Non-Steroidal Anti-Inflammatory Agents (NSAIDs)IBA 08/2004
1	Cyclooxygenase 2 Inhibitors (COX-2 Inhibitors)IBA 08/2004
1	Cyclooxygenase 1IBA 08/2004

Therapy/Procedure

1	Reoperation 02/2013
1	Hip Replacement Arthroplasty (Total Hip Replacement) 02/2013
1	Prostheses and Implants (Prosthesis) 02/2013
1	Pain Management 01/2012
1	Therapeutics 08/2004
1	Conservative Treatment 02/2002